A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview We are a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. Our lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (“IBD”), including ulcerative colitis (“UC”) and Fibrostenotic Crohn’s disease (“FSCD”). Our Strategy Our objective is to establish ourselves as a leader in the development of differentiated product candidates targeting the autoimmune, inflammatory, and fibrotic disease markets, which we believe will address a large, well-established need among patients living with autoimmune and inflammatory diseases.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 250K | 0 | - | - |
| Net Income | -11M | -14M | - | - | -16M | -8.4M |
| EPS | $-2.07 | $-10.19 | $-27.01 | $-247.95 | $-5,265.00 | $-17,100.00 |
| Free Cash Flow | 0 | -12M | -11M | -13M | -9.0M | -7.3M |
| ROIC | -129.8% | -156.7% | - | - | -86.3% | -103.6% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.45 | 0.24 | 0.26 | 0.34 | 0.05 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -11M | -15M | -13M | -16M | -11M | -8.6M |
| Operating Margin | 0.0% | - | -5228.0% | - | - | - |
| ROE | -349.5% | -153.6% | - | - | -218.4% | -162.9% |
| Shares Outstanding | 149M | 4M | 4M | 1M | 0M | 0M |
PALISADE BIO, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
PALISADE BIO, INC. (PALI) has a 5-year average return on invested capital (ROIC) of -115.5%. This is below average and may indicate limited pricing power.
PALISADE BIO, INC. (PALI) has a market capitalization of $297M. It is classified as a small-cap stock.
PALISADE BIO, INC. (PALI) does not currently pay a regular dividend.
PALISADE BIO, INC. (PALI) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
PALISADE BIO, INC. (PALI) generated $-12 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PALISADE BIO, INC. (PALI) has a debt-to-equity ratio of 0.45. This indicates a conservatively financed balance sheet.
PALISADE BIO, INC. (PALI) reported earnings per share (EPS) of $-10.19 in its most recent fiscal year.
PALISADE BIO, INC. (PALI) has a return on equity (ROE) of -153.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 14 years of financial data for PALISADE BIO, INC. (PALI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PALISADE BIO, INC. (PALI) has a book value per share of $1.70, based on its most recent annual SEC filing.